AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary disease (COPD) trial will throw their plans for the anti-IL-33 monoclonal ...
CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death ...
LONDON, May 11 (Reuters) - AstraZeneca Plc's experimental heart drug Brilinta has beaten Sanofi-Aventis SA and Bristol-Myers Squibb Co's blockbuster Plavix in a pivotal clinical trial, lifting its ...
AstraZeneca's Oncology and Rare Disease segments delivered 16% and 15% growth, powered by IMFINZI and ULTOMIRIS, respectively ...
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
CHICAGO - Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results